{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"61"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered related to study drug. AEs were classified by the Investigator using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.","groups":[{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks based on available data from the Phase 1 (JZP458-101) healthy volunteer study.","id":"OG000","title":"Part A: JZP-458 IM 25 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 37.5 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG001","title":"Part A: JZP-458 IM 37.5 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG002","title":"Part A: JZP-458 IM 25 (MW)/50 mg/m^2 (F)"},{"description":"Participants who received an intravenous (IV) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG003","title":"Part B: JZP-458 IV 25 (MW)/50 mg/m^2 (F)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety events were assessed in the Safety Analysis Set.","reportingStatus":"POSTED","timeFrame":"Date of written informed consent up to 30 days after last dose of last course, up to approximately 2 years 7 months","title":"Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}